Myriad Genetics
在场
是其中之一......
Myriad Genetics 是一家在股票代码 MYGN (US) 下上市的公司。
Myriad Genetics 在 2 个国家有直接业务。Myriad Genetics 拥有 4家子公司，其中包括 GeneSight、Myriad Genetics Europe 和 Myriad RBM。
他们在：
高管
查看带有其 43 名主要高管的组织结构图
Myriad Genetics 搜索最多的简介
- Paul Diaz, Director, President and Chief Executive Officer
- Heiner Dreismann, Director
- Lee Newcomer, Director
高管在Myriad Genetics变化
- Jennifer Fox已作为Chief Legal Officer加入公司 (新闻发布的2024八月1号).
创建提醒
跟踪 Myriad Genetics 的高管变动
药店
Myriad Genetics 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
Myriad Genetics 的最新新闻稿
- Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
- Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
- Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
- NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
- Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
- Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
- Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
- Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
- Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
- Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
- View more press releases Close
通过电子邮件
